- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01793779
Comparison of Pre-exercise Beta-hydroxy-beta-methylbutyrate Free Acid (HMB-FA) and Cold Water Therapy for the Attenuation of Muscle Damage and Soreness
Comparison of Pre-exercise Beta-hydroxy-beta-methylbutyrate Free Acid (HMB-FA) and Cold Water Therapy for the Attenuation of Muscle Damage and Soreness in Experienced Resistance Trained Individuals.
Study Objectives
- Compare beta-hydroxy-beta-methylbutyrate free acid (HMB-FA) to cold water immersion on performance recovery from an acute bout of high intensity resistance exercise.
- Compare HMB-FA + Cold water immersion to HMB-FA or cold water immersion.
- Examine the effect of these recovery modalities on markers of muscle damage, inflammation and immune function.
Subjects
Subjects (men and women, 18 - 35 y) with at least one year of resistance training experience will be recruited. Subjects will be randomly divided into one of four groups: a cold water immersion group (CW), HMB-FA, CW+HMB-FA and a control group (CT).
Study Protocol
Subjects will report to the Human Performance Laboratory (HPL) on four separate occasions. On the first visit (T1) subjects will be tested for maximal strength [one repetition-maximum (1-RM)] on the squat, dead lift and barbell lunge exercises.] On their second visit (T2) subjects will perform a lower body resistance exercise session consisting of four sets of the squat, dead lift and barbell lunge exercises. All subjects will then report back to the HPL at 24- (T3) and 48-hours (T4) post-exercise. During T3 and T4, subjects will perform four sets of the squat exercise only using the same loading pattern and rest interval length as T2. Following the T2 and T3 workouts subjects in CT will undergo no treatment; subjects in CW will be required to sit in a whirlpool tub for 10-min up to their umbilicus in water at 50° F - 54° F (10° C - 12° C); subjects in HMB-FA will be provided the supplement 30 min prior each workout and CW+HMB-FA will be administered together at time points describe above.
Statistical Analysis
Statistical evaluation of performance and biochemical changes will be accomplished using a repeated measures analysis of variance (ANOVA).
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Orlando, Florida, United States, 32816
- University of Central Florida, Sport and Exercise Science
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least one-year of resistance training experience
- Free of any physical limitations (determined by health and activity questionnaire).
- Between the ages of 18 and 35
Exclusion Criteria:
- Inability to perform physical exercise (determined by health and activity questionnaire)
- Taking any other nutritional supplement or performance enhancing drug (determined from health and activity questionnaire).
- Any chronic illness that causes continuous medical care
- Taking any type of prescription or over-the-counter medication, having any chronic illness causing you to seek medical care, pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Control
Placebo supplement given prior to exercise and two times per day following exercise
|
|
|
Experimental: cold water immersion
Placebo supplement to be give prior to exercise and two times per day following exercise in combination with cold water immersion therapy following exercise
|
|
|
Experimental: HMB-FA
beta-hydroxy-beta-methylbutyrate free acid supplement to be give prior to exercise and two times per day following exercise
|
|
|
Experimental: cold water immersion group + HMB-FA
beta-hydroxy-beta-methylbutyrate free acid supplement give prior to exercise and two times per day following exercise in combination with cold water immersion therapy following exercise
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximal muscle strength
Time Frame: Change from baseline over 48 hours post-exercise.
|
The 1-RM tests will be performed to assess maximal muscle strength.
|
Change from baseline over 48 hours post-exercise.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Muscle damage
Time Frame: Change from baseline over 48 hours post-exercise.
|
Serum creatine kinase and myoglobin concentrations will be analyzed as markers of muscle damage.
|
Change from baseline over 48 hours post-exercise.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Muscle soreness
Time Frame: Change from baseline over 48-hours post-exercise.
|
Subjects will be asked to rate their degree of lower body muscle soreness using a 15-cm visual analog scale (VAS).
|
Change from baseline over 48-hours post-exercise.
|
|
Lower body power
Time Frame: Change from baseline over 48 hours post-exercise.
|
Lower body power during the squat exercise protocol will be measured each repetition with a Tendo™ Power Output Unit.
|
Change from baseline over 48 hours post-exercise.
|
|
Immune Markers
Time Frame: Change from baseline over 48 hours post-exercise.
|
Immune (IL-6, IL-10, Macrophage inflammatory protein-1β, tumor necrosis factor-α) markers will be analyzed.
|
Change from baseline over 48 hours post-exercise.
|
|
C-reactive protein
Time Frame: Change from baseline over 48 hours post-exercise.
|
The Inflammatory marker, C-reactive protein, will be analyzed.
|
Change from baseline over 48 hours post-exercise.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Ascensao A, Leite M, Rebelo AN, Magalhaes S, Magalhaes J. Effects of cold water immersion on the recovery of physical performance and muscle damage following a one-off soccer match. J Sports Sci. 2011 Feb;29(3):217-25. doi: 10.1080/02640414.2010.526132.
- Fuller JC Jr, Sharp RL, Angus HF, Baier SM, Rathmacher JA. Free acid gel form of beta-hydroxy-beta-methylbutyrate (HMB) improves HMB clearance from plasma in human subjects compared with the calcium HMB salt. Br J Nutr. 2011 Feb;105(3):367-72. doi: 10.1017/S0007114510003582. Epub 2010 Dec 7.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- MTI2013-CS01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Muscle Damage
-
University of ThessalyCompletedAthletic Performance | Muscle Damage | Skeletal Muscle DamageGreece
-
PepsiCo Global R&DRecruitingMuscle Damage | MuscleUnited States
-
University of SaskatchewanCompleted
-
University of New MexicoWithdrawn
-
University of SurreyCompletedMuscle DamageUnited Kingdom
-
Federal University of Health Science of Porto AlegreCompleted
-
Federal University of Health Science of Porto AlegreCompleted
-
Tel Aviv UniversityNot yet recruiting
-
Instituto de Ciencias de la Salud, Universidad...University of Manitoba; Universidad Nacional Andres BelloCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States